Mycophenolate Mofetil vs Mycophenolic Acid: Different Formulations of the Same Active Drug
Mycophenolate mofetil (MMF) and mycophenolic acid (MPA) are not the same drug but are therapeutically equivalent formulations that deliver the same active metabolite—mycophenolic acid—though they differ in dosing, absorption, and cannot be interchanged without physician supervision. 1
Pharmacological Relationship
MMF is a prodrug that is rapidly converted to MPA, the pharmacologically active compound. 1, 2 After oral administration, MMF undergoes pre-systemic metabolism to release mycophenolic acid, which then exerts immunosuppressive effects by inhibiting inosine monophosphate dehydrogenase (IMPDH), thereby blocking lymphocyte proliferation. 3, 4
The key formulations available are:
- Mycophenolate mofetil (MMF): The original prodrug formulation 2
- Enteric-coated mycophenolate sodium (EC-MPS): Also known as mycophenolic acid delayed-release tablets, designed to reduce gastrointestinal side effects 1
Critical Dosing Differences
The two formulations require different doses because they are not bioequivalent and have different rates of absorption. 5
Dose Equivalency:
- 720 mg of enteric-coated MPA (EC-MPS) is roughly equivalent to 1,000 mg of MMF 5
- For typical dosing: 720-1,080 mg MPA twice daily approximates 2-3 g total daily dose of MMF 5
The FDA explicitly warns that mycophenolic acid delayed-release tablets and MMF should not be used interchangeably without physician supervision because the rate of absorption is not equivalent. 1
Clinical Equivalence and Practical Considerations
Multiple guidelines confirm that MMF and MPA formulations are likely to be therapeutically equivalent in clinical efficacy. 5 Evidence from transplantation medicine and lupus nephritis trials suggests equal efficacy when appropriately dosed. 5
Gastrointestinal Tolerability:
Some evidence suggests that enteric-coated MPA may cause less nausea and diarrhea compared to MMF, though this remains controversial. 5 For patients experiencing gastrointestinal side effects with MMF, switching to the enteric-coated MPA formulation at equivalent doses (720-1,080 mg twice daily) is a reasonable strategy. 5
Administration Requirements
Both formulations should be taken on an empty stomach (1 hour before or 2 hours after food) to maintain optimal absorption. 1 The enteric-coated tablets must be swallowed whole and should not be crushed, chewed, or cut, as this would compromise the enteric coating. 1
Common Pitfalls to Avoid
- Never substitute one formulation for another at the same milligram dose—this will result in either under- or over-immunosuppression 1
- Do not switch between generic formulations or between innovator and generic products without careful monitoring, as therapeutic equivalence between generics is not guaranteed 6
- When converting from MMF to EC-MPS or vice versa, use the established dose conversion ratio (approximately 1.4:1 ratio of MMF to EC-MPS) 5